340B Advocacy Alliance Bulletin
Johnson & Johnson yesterday filed a lawsuit against the Department of Health and Human Services and the Health Resources and Services Administration asking a federal court in Washington, D.C., to declare J&J’s proposed 340B rebate model legal and block the government’s attempts to prohibit…
AHA releases Regulatory Advisory summarizing CMS final guidance on implementation of the Medicare Drug Price Negotiation Program
The AHA, 340B Health, the Minnesota Hospital Association and American Society of Health-System Pharmacists Oct. 4 filed two amicus briefs in the U.S. District Court for the District of Minnesota, defending the state's law protecting 340B pricing for contract pharmacy arrangements.
The Department of Health and Human Services Oct. 2 released final guidance detailing the process for the second cycle of negotiations under the Medicare Drug Price Negotiation Program.
A Louisiana district court yesterday upheld a state law prohibiting drug companies from denying Louisiana hospitals 340B discounts for drugs dispensed at community pharmacies.
As urged by the AHA and others, J&J tells HRSA it is abandoning proposed 340B rebate plan.
The Health Resources and Services Administration today sent a final warning letter to Johnson & Johnson urging the company to inform the agency by Monday, Sept. 30 that it would halt its proposed 340B rebate model scheduled to go into effect next month.
The deadline has been extended for representatives to sign onto a letter that urges the Department of Health and Human Services to take action to stop Johnson & Johnson’s plan “to upend more than 30 years of federal law by delaying access to 340B Drug Pricing Program (340B) discounts on…
Urge your representatives to sign letter to HHS asking it to take action to protect providers from ‘devastating’ J&J 340B proposal; deadline is Sept. 20.
The Health Resources and Services Administration today told Johnson & Johnson that the company’s publicly announced plans to implement a 340B rebate model “violates J&J’s obligations under the 340B statute, and HRSA expects J&J to cease implementation of it.”